China Orders Stepped-Up Oversight Of Heparin Production
This article was originally published in PharmAsia News
China's State FDA has ordered increased supervision and inspection of drug makers producing the blood thinner heparin. The order went out to FDA bureaus around the country to make sure companies follow regulations while producing the material. Bureau chiefs are to make sure producers obtain raw heparin only from registered suppliers and the suppliers in turn strengthen their own oversight of raw and supplementary materials. Drug makers also are being advised to track production carefully and recall any product that has possible safety problems. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.